Condition: Non Small Cell Lung Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal and Leptomeningeal Metastases
This description comes directly from the study's public registry record.
Maobin Meng, MD · +86 15202231270 · mmeng@tmu.edu.cn
Always discuss trial participation with your own doctor first.
| CANGZHOU People's Hospital | Cangzhou, Hebei, China | Recruiting |
| Tianjin medical university cancer hospital and institute | Tianjin, Tianjin Municipality, China | Recruiting |
| Tianjin Huanhu Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07304739